Medical device solutions and services.
DJO is a global provider of high-quality medical devices that provide proven solutions for musculoskeletal health, joint reconstruction, vascular health, and pain management. Colfax Corporation acquired DJO in the first quarter of 2019 as our inaugural investment in our new strategic growth platform in the medical technology space.
Activity is the key to a better lifestyle, better treatment outcomes, and improved healthcare economics for all. That’s why DJO was founded on the philosophy of helping to get and keep people moving. DJO offers healthcare providers and patients a complete Orthopedic Continuum of Care, from performance and mobility to surgical intervention and postoperative rehabilitation.
AltiVate Reverse® Short Stem.
In 2019, DJO released the AltiVate Reverse Short Stem, the first fully convertible, inlay, short stem shoulder arthroplasty system available in the United States – giving the more than 50,000 people in the US who have shoulder replacement surgery each year a new option. Its bone-sparing, short-stem, innovative 135-degree neck-shaft angle sits entirely within the humerus, allowing for easy conversion from anatomic to reverse shoulder arthroplasty.
Creating better motion together.
Populations are aging, and healthcare costs are rising. Keeping people active is more important than ever. With the backing of Colfax, DJO is tackling these challenges head-on by not only enabling movement with innovative products and solutions, but also relentlessly looking for ways to drive continuous improvement and deliver additional value to patients, healthcare providers, and shareholders.
How CBS is working for DJO.
Since being acquired by Colfax, DJO has been able to implement Colfax Business System tools to identify product development opportunities, improve operational efficiency, and expand margins. In the first year alone, DJO’s past dues decreased by more than 70%, and fill rates increased to 90%. As a result of these improvements in operational efficiency, core growth in 2019 steadily improved quarter over quarter, reaching 5.5% in Q4.
Med tech quarterly year-over-year core growth
Fill rate up 20% in first year